On this investor day, Zhao Wei, vice president and head of research and development of Zhengda Tianqing, revealed that at present, the company's layout of the top ten biological drug targets in the world has reached 90%, and 8 biosimilar drugs have completed the first listing declaration, ranking second in the number of applications in China; The nine product progress is the top three in China, all of which are high-potential varieties with sales of more than 1 billion yuan.
At the same time, the company is also actively layout the global market, product sales involve Europe, Southeast Asia, Africa, South America, Central and North America and other regions. And Limoprost, polymyxin B and other heavy generic varieties are expected to be rapidly expanded this year, which will drive the overall steady growth of performance.
email:1583694102@qq.com
wang@kongjiangauto.com